AstraZeneca, Lilly feeling real pain in race for arthritis drugs
[column width=”360px” padding=”20px”]The supercharged race to get new treatments into the lucrative market for treating rheumatoid arthritis (RA) appeared to thin considerably today as one contender dropped a study and another’s drug came up short against the existing competition. Keep Reading